Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1055625 | 0.98 | EPHX1 (0.36) | EPHX1EPHX2ALDH1A1THRBATM | |
| Hydrochloric Acid SCHEMBL2640463 | 0.98 | EPHX1 (0.36) | EPHX1EPHX2ALDH1A1THRBATM | |
| Propane SCHEMBL27918189 | 0.90 | EPHX2 (0.39) | EPHX1EPHX2ALDH1A1THRBATM | |
| SCHEMBL3932214 | 0.82 | KDM1A (0.43) | EPHX1EPHX2ALDH1A1THRBATM | |
| SCHEMBL13852062 | 0.80 | EPHX2 (0.56) | EPHX1EPHX2 | |
| SCHEMBL1308573 | 0.79 | THRB (0.46) | EPHX1EPHX2ALDH1A1THRBATM | |
| Hydrochloric Acid SCHEMBL4163207 | 0.78 | EPHX2 (0.55) | EPHX1EPHX2 | |
| Hydrochloric Acid SCHEMBL30876210 | 0.78 | EPHX2 (0.55) | EPHX1EPHX2 | |
| SCHEMBL16322031 | 0.78 | EPHX1 (0.42) | EPHX1EPHX2ALDH1A1HTT | |
| SCHEMBL12819911 | 0.77 | EPHX1 (0.37) | EPHX1EPHX2ALDH1A1THRBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023122778-A1 | PYRIDAZINONE DERIVATIVES USEFUL AS T CELL ACTIVATORS | GOSSAMER BIO SERVICES, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-10800741-B2 | Quinoline compound, preparation method and medical use therefor | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2020-10-13 | — | — | US | disclosed |
| CN-107001332-A | New piperidine derivative | 豪夫迈·罗氏有限公司 | 2017-08-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800741-B2 | Quinoline compound, preparation method and medical use therefor | WEE2, WEE1, HASPIN | EPHX1 1886/4885EPHX2 2964/4885ALDH1A1 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.